Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 779-786 |
| Number of pages | 8 |
| Journal | Annals of Hematology |
| Volume | 96 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Cite this
Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. / Castelli, R; Sciara, S; Lambertenghi Deliliers, G; Pantaleo, G.
In: Annals of Hematology, Vol. 96, No. 5, 2017, p. 779-786.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study
AU - Castelli, R
AU - Sciara, S
AU - Lambertenghi Deliliers, G
AU - Pantaleo, G
PY - 2017
Y1 - 2017
N2 - Anaemia is a complication reported in up to 70% of the multiple myeloma patients (MM), with remarkable clinical, cognitive and socio-relational consequences. Anaemia relates to the course of MM, normalizing in patients during remission and reappearing in relapsing/non-responding patients. In a pilot study with 31 patients with MM and transfusion-dependent anaemia, we evaluated the effects of Binocrit (biosimilar epoetin alfa) on transfusions, haemoglobin levels, mental status (mini-mental state evaluation) and the patients’ social-relational functioning and quality of life (QoL). Within a 12-week interval, patients received 40.000 U Binocrit once a week. Binocrit significantly decreased the incidence of transfusion, regardless of the patients’ transfusion history, and significantly increased haemoglobin levels (before-and-after-treatment median haemoglobin values = 8.20 vs. 9.40 g/dl, respectively; Wilcoxon Z test, p
AB - Anaemia is a complication reported in up to 70% of the multiple myeloma patients (MM), with remarkable clinical, cognitive and socio-relational consequences. Anaemia relates to the course of MM, normalizing in patients during remission and reappearing in relapsing/non-responding patients. In a pilot study with 31 patients with MM and transfusion-dependent anaemia, we evaluated the effects of Binocrit (biosimilar epoetin alfa) on transfusions, haemoglobin levels, mental status (mini-mental state evaluation) and the patients’ social-relational functioning and quality of life (QoL). Within a 12-week interval, patients received 40.000 U Binocrit once a week. Binocrit significantly decreased the incidence of transfusion, regardless of the patients’ transfusion history, and significantly increased haemoglobin levels (before-and-after-treatment median haemoglobin values = 8.20 vs. 9.40 g/dl, respectively; Wilcoxon Z test, p
U2 - 10.1007/s00277-017-2950-9
DO - 10.1007/s00277-017-2950-9
M3 - Article
VL - 96
SP - 779
EP - 786
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 5
ER -